Gradientech receives QuickMIC® order from Iberlab in Portugal

Report this content

The diagnostic company Gradientech today announces the first order from their recently assigned distributor in Portugal.

Iberlab is a leading supplier of diagnostic solutions and consumables to clinical laboratories in Portugal and was recently assigned as the commercial partner of Gradientech in the Portuguese market. Iberlab’s first installation of the QuickMIC® system is at Hospital Espirito Santo Évora.

“It´s encouraging to see that the QuickMIC system is already out on its first commercial evaluation in Portugal. Portugal is an important market for us, with the need for rapid susceptibility testing driven by the relatively high antibiotic resistance levels in society”, says Peter Karlberg, VP Sales at Gradientech.

“At Iberlab, we are very grateful for the fast and professional support given by Gradientech when we now start to roll out the system. We are very excited about our first evaluation to demonstrate all the advantages of the fastest AST system in the market”, comments João Teixeira, CEO of Iberlab.

The QuickMIC system's ultra-rapid and precise results enable sepsis patients to quickly receive specific personalised guidance of the right antibiotics in the right dose. The modular design of the system makes it possible for hospital labs to start on a small scale and expand with more modules depending on needs. The QuickMIC system and its Gram-negative panel are CE-marked and commercially available in Europe but not yet available for sale in the United States.

For further information, please contact:
Peter Karlberg, VP Sales Gradientech

Tel: + 46 763 29 08 14
peter.karlberg@gradientech.se

Sara Thorslund, PhD, CEO Gradientech

Tel: +46 736 29 35 80

sara.thorslund@gradientech.se

 

About Gradientech

Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.